American Academy of Dermatology

The durability of both skin clearance and itch reduction extended up to 4 years of lebrikizumab use in this assessment of adults and adolescents with atopic dermatitis.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

Phase 3 data on rademikibart in moderate-to-severe atopic dermatitis (AD) have been released from the AAD late-Breaking research session.

These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.

This interview highlights phase 3 findings on sonelokimab for individuals with hidradenitis suppurativa (HS).

This interview highlights new 12-month, real-world data on tralokinumab and its long-term efficacy in patients with skin of color who live with atopic dermatitis.

Patients with non-segmental vitiligo (NSV) on upadacitinib versus placebo showed continuous improvement over 48 weeks with no plateau.

Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.

Results from the phase 3 trial were published in NEJM and simultaneously presented as a late-breaking abstract at AAD 2026.

This interview with David Cotter, MD, PhD, highlights recent findings and new data in the psoriasis treatment space highlighted at AAD 2026.

New late-breaking phase 3 data suggest zasocitinib may help reshape the oral treatment landscape for moderate-to-severe plaque psoriasis.

In this segment of his interview, Eichenfield highlights the safety and tolerability of roflumilast cream for children with atopic dermatitis in INTEGUMENT-OLE.

The IMMpactful direct comparison provides prospective data in a moderate psoriasis population that previous MAICs could not fully capture.

These 52-week, phase 3 data on icotrokinra, presented at AAD, highlight the drug's efficacy and safety among adults with moderate to severe plaque psoriasis.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Rosmarin discussed new late-breaking data from ADVANCE-AA at AAD 2026.

This late-breaking, phase 2 data highlights nemolizumab's clinically meaningful benefits for children with moderate-to-severe atopic dermatitis.

Soung discussed how new 52-week data support icotrokinra's recent FDA approval, marketed as Icotyde.

This interview at AAD 2026 highlights Nguyen's views on the biggest drivers of patient dissatisfaction in dermatology practice settings.

Tildrakizumab is US FDA-approved for treating adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

This interview at AAD 2026 highlights tips for clinicians in dermatology practices who want to improve patient communication and satisfaction.

These new data on spesolimab (Spevigo) in adults with generalized pustular psoriasis highlight long-term findings with the treatment.

A post-hoc analysis of phase 3 trials found tapinarof cream 1% produced skin clearance and itch relief as early as week 1 in patients aged 2 years and older.

Janiene Luke, MD, co-chair of the Skin of Color Society (SOCS) Scientific Symposium, speaks about complex cases in dermatology and other topics covered at the meeting.

Temitayo Ogunleye, MD, co-chair of the Skin of Color Society Scientific Symposium, speaks with HCPLive about the meeting's guiding theme and topics.

Chris Bunick, MD, PhD, and Lindsay Ackerman, MD, preview the 2026 American Academy of Dermatology Annual Meeting.